Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical UniversityВестник Волгоградского государственного медицинского университета1994-94801994-9499Volgograd State Medical University11926510.19163/1994-9480-2018-2(66)-125-130ArticlesСтатьиReview ArticleNON-ALCOHOLIC FATTY LIVER DISEASE -A NEW RISK FACTOR FOR THE DEVELOPMENT OF CHRONIC KIDNEY DISEASEНЕАЛКОГОЛЬНАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ - НОВЫЙ ФАКТОР РИСКА РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕКStatsenkoM. EСтаценкоМихаил Евгеньевич

д. м. н., профессор, зав. кафедрой внутренних болезней педиатрического и стоматологического факультетов

mestatsenko@rambler.ruTurkinaS. VТуркинаС. В

кафедра внутренних болезней педиатрического и стоматологического факультетов

ErmolenkoA. AЕрмоленкоА. А

кафедра внутренних болезней педиатрического и стоматологического факультетов

GorbachevaE. EГорбачеваЕ. Е

кафедра внутренних болезней педиатрического и стоматологического факультетов

SabanovA. VСабановА. В

кафедра внутренних болезней педиатрического и стоматологического факультетов

FSBEI HE «Volgograd State Medical University» of Public Health Ministry of the Russian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации15022018152NO2 (2018)№2 (2018)12513018122022Copyright ©; 2018, Statsenko M.E., Turkina S.V., Ermolenko A.A., Gorbacheva E.E., Sabanov A.V.Copyright ©; 2018, Стаценко М.Е., Туркина С.В., Ермоленко А.А., Горбачева Е.Е., Сабанов А.В.2018Statsenko M.E., Turkina S.V., Ermolenko A.A., Gorbacheva E.E., Sabanov A.V.Стаценко М.Е., Туркина С.В., Ермоленко А.А., Горбачева Е.Е., Сабанов А.В.https://creativecommons.org/licenses/by/4.0https://journals.eco-vector.com/1994-9480/article/view/119265

The review presents data on the frequency of occurrence of chronic kidney disease in patients with non-alcoholic fatty liver disease. The main pathogenetic mechanisms of the formation of chronic kidney disease in patients with non-alcoholic fatty liver disease.

В обзоре представлены данные по частоте встречаемости хронической болезни почек у пациентов с неалкогольной жировой болезнью печени. Обсуждаются основные патогенетические механизмы формирования хронической болезни почек у пациентов с неалкогольной жировой болезнью печени.

non-alcoholic fatty liver diseasechronic kidney diseaseнеалкогольная жировая болезнь печенихроническая болезнь почекAdesso S., Popolo A., Bianco G., et al. The uremic toxin indoxyl sulphate enhances macro-phage response to LPS. PLoS One, 2013, no. 8, p. 76778.Adepu S., Katta K., Tietge U.J., et al. Hepatic syndecan-1 changes associate with dyslipidemia after renal transplantation. Am. J. Transplant., 2014, no. 14, pp. 2328-2338.Armstrong M.G., Houlihan D.D., Bentham L., Shaw J.C et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol., 2012, no. 56 (1), pp. 234-240.Armstrong M.J., Adams L.A., Canbay A., Syn W.K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014, no. 59, pp. 1174-1197.Bridgewater D.J. The role of the type I insulin-like growth factor receptor (IGF-IR) in glomerular integrity. Growth Horm. IGF Res., 2008, no. 18, pp. 26-37.Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol., 2015, no. 62 (1 Suppl.), pp. 47-64.Caravaca F., Cerezo I., Macias R. et al. Insulin resistance in chronic kidney disease: its clinical characteristics and prognosis significance. Nefrologia, 2010, no. 30 (6), pp. 661-668.Chang Y., Ryu S., Sung E., et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism, 2008, no. 57, pp. 569-576.Choi Y.J., Shin H.S, Choi H.S., et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab. Invest., 2014, no. 94, pp. 1114-1125.Cianfarani S. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J. Pediatr., 2014, no. 165, pp. 92-98.Colak Y., Senates E., Ozturk O., et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur. J. Gastroenterol. Hepatol., 2012, no. 24, pp. 255-261.Deng Y., Foley E.M., Gonzales J.C., et al. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology, 2012, no. 55, pp. 277-286.de Vries A.P., et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol., 2014, no. 2, pp. 417-426.Gyebi L., Soltani Z., Reisin E. Lipid nephro- toxicity: new concept for an old disease. Curr. Hypertens. Rep., 2012, no. 14, pp. 177-181.Herman-Edelstein M., Scherzer P., Tobar A., Levi et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid. Res., 2014, no. 55, pp. 561-572.Ishimoto T. et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology, 2013, no. 58, pp. 1632-1643.Jiang S. et al. Fibroblast growth factor 21 is regulated by the IRE1/-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem., 2014, no. 289, pp. 29751-29765.Koppe L., Pillon N.J., Vella R.E., et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J. Am. Soc. Nephrol., 2013, no. 24, pp. 88-99.Lanaspa, M.A. et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J. Am. Soc. Nephrol., 2014, no. 25, pp. 2526-2538.Lubel J.S., Herath C.B., Burrell L.M., Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J. Gastroenterol. Hepatol., 2008, no. 23 (9), pp. 1327-38.Massiera F., Bloch-Faure M., Ceiler D., Murakami K., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J, 2009, no. 15 (14), pp. 2727-2729.Morris E.M. et al. The role of angiotensin II in nonalcoholic steatohepatitis. Mol. Cell. Endocrinol., 2013, no. 378, pp. 29-40.Muller-Wieland D., Kotzka J. SREBP-1: gene regulatory key to syndrome X? Ann. N. Y. Acad. Sci., 2002, no. 967, pp. 19-27.Musso G., Gambino R., Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med., 2011, no. 62, pp. 361-380.Musso G., Cassader M., Olivetti C., et al. Association of obstructive sleep apnoea with the presence and severity of nonalcoholic fatty liver disease. A systematic review and meta-analysis. Obes. Rev., 2013, no. 14, pp. 417-431.Musso G., Gambino R., Tabibian J.H, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med, 2014, no. 1, p. 1001680.Musso G., Cassader M., Cohney S., et al. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends in Molecular Medicine, 2015, no. 21 (10), pp. 645-662.Nymark M., Pussinen P.J., Tuomainen A.M., Forsblom C., et al; FinnDiane Study Group. Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with type 1 diabetes. Diabetes Care, 2009, no. 32, pp. 1689-1693.Padberg J.S., Wiesinger A., di Marco G.S., et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis, 2014, no. 234, pp. 335-343.Pawlak M., Baugeÿ E., Bourguet W., et al. The transrepressive activity of peroxisome proliferator - activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology, 2014, no. 60, pp. 1593-1606.Pelletier C.C. et al. White adipose tissue overproduces the lipid-mobilizing factor zinc /2-glycoprotein in chronic kidney disease. Kidney Int., 2013, no. 83, pp. 878-886.Ron D., Brasier A.R., Habener J.F. Transcriptional regulation of hepatic angiotensinogen gene expression by the acute-phase response. Mol. Cell. Endocrinol., 1990, no. 74 (3), pp. 97-104.Sesti, G. et al. IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: a study in obese, but metabolically healthy, subjects and obese, insulin-resistant subjects // Nutr. Metab. Cardiovasc. Dis. 2-11, no. 21, pp. 933-940.Sinn D.H., Kang D., Jang H.R., et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J. Hepatol., 2017, no. 67 (6), pp. 274-1280.Sit D., Kadiroglu A.K., Kayabasi H., Yilmaz M.E. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv. Ther., 2000, no. 23 (6), pp. 988-998.Souza-Mello V. Peroxisome proliferator- activated receptors as targets to treat non- alcoholic fatty liver disease. World J. Hepatol., 2015, no. 7, pp. 1012-1019.Tang W.H., Wang Z., Kennedy D.J., et al. Gut Microbiota-Dependent Trimethylamine. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res., 2015, no. 116, pp. 448- 455.Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia, 2008, no. 51, pp. 444-450.Targher G., Chonchol M., Bertolini L., et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol., 2010, no. 5, pp. 2166-2171.Unger R.H. Lipotoxic diseases. Annu. Rev. Med., 2002, no. 53, pp. 319-336.Vaziri N.D., Yuan J., Nazertehrani S., Ni Z., Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am. J. Nephrol., 2013, no. 38, pp. 99-103.Wang Y., van der Tuin S., Tjeerdema N., et al. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology, 2015, no. 62, pp. 1710-1722.Woo YC. et al. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol., 2013, no. 78, pp. 489-496.Wong J., Piceno Y.M., Desantis T.Z., et al. Expansion of urease- and uricase-containing, indole- and p-cresol- forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol., 2014, no. 39, pp. 230-237.Xin W., Zhao X., Liu L., et al. Acetyl-CoA car-boxylase 2 suppression rescues human proximal tubular cells from palmitic acid induced lipotoxicity via autophagy. Biochem. Biophys. Res. Commun., 2015, no. 463, pp. 364-369.Xu Y., Huang J., Xin W., et al. Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy. Metabolism, 2014, no. 63, pp. 716-726.Yilmaz Y., Eren F., Colak Y., et al. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand. J. Gastroenterol., 2012, no. 47, pp. 1488-1493.Zobair M., Aaron B. Koenig, Dinan Abdelatif, et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease- Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 2016, no. 64 (1), pp. 73-84.Zhu P. et al. Serum uric Acid is associated with incident chronic kidney disease in middle-aged populations: a meta-anal-50. Analysis of 15 cohort studies. PLoS ONE, 2014, no. 9, p. 100801.